Compare BRKR & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRKR | STVN |
|---|---|---|
| Founded | 1960 | 1949 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Containers/Packaging |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 5.4B |
| IPO Year | 2000 | 2021 |
| Metric | BRKR | STVN |
|---|---|---|
| Price | $50.14 | $16.84 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 2 |
| Target Price | ★ $51.69 | $23.75 |
| AVG Volume (30 Days) | ★ 2.3M | 521.3K |
| Earning Date | 02-12-2026 | 03-05-2026 |
| Dividend Yield | ★ 0.40% | 0.37% |
| EPS Growth | N/A | ★ 19.61 |
| EPS | N/A | ★ 0.60 |
| Revenue | ★ $3,438,900,000.00 | $1,373,219,524.00 |
| Revenue This Year | $3.58 | $8.42 |
| Revenue Next Year | $1.46 | $9.61 |
| P/E Ratio | ★ N/A | $28.89 |
| Revenue Growth | 6.10 | ★ 6.97 |
| 52 Week Low | $28.53 | $16.30 |
| 52 Week High | $60.09 | $28.00 |
| Indicator | BRKR | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 51.79 | 26.14 |
| Support Level | $46.82 | $18.80 |
| Resistance Level | $53.50 | $19.94 |
| Average True Range (ATR) | 2.56 | 0.97 |
| MACD | -0.25 | -0.28 |
| Stochastic Oscillator | 33.40 | 12.28 |
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.